

Doc. ID: SDS-002 EN Revision: 01

Revision date: April 27, 2020

#### **SECTION 1. IDENTIFICATION**

#### 1.1 Product Identifier

| Product Name:   | Other Means of Identification. Catalog #: |  |
|---|---|--|
| CRYO <i>check</i> ™ Factor VIII Inhibitor Kit: Imidazole Buffered Pooled Normal Plasma (IB-PNP) Component | CCIK08, IB-PNP Component                  |  |

Product type: Liquid

#### 1.2 Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Recommended Use: For use with the other components of CRYOcheck Factor

VIII Inhibitor Kit.

CRYO*check*™ Factor VIII Inhibitor Kit is a medical device

for in vitro diagnostic use

Restrictions on Use: For professional use only

1.3 Details of the Supplier of the Safety Data Sheet

Manufacturer Contact Information: Precision BioLogic Inc., 140 Eileen Stubbs Ave Dartmouth,

NS B3B 0A9, Canada

Email: <a href="mailto:techsupport@precisionbiologic.com">techsupport@precisionbiologic.com</a>

Precision BioLogic Inc. Telephone Number: <u>1-800-267-2796</u>

1.4 Emergency Telephone Number

USA Poison Control: 1-800-222-1222

Canada Provincial Poison Control Centers: www.capcc.ca

EU National Helpdesks: https://echa.europa.eu/support/helpdesks



Doc. ID: SDS-002 EN Revision: 01

Revision date: April 27, 2020

### **SECTION 2. HAZARD IDENTIFICATION**

#### 2.1 Classification of the Mixture

|     | This product is classified according to Regulations (EC) No 1272/2008 and OSHA 29CFR 1910.1200 |   |  |  |  |  |
|-----|--|---|--|--|--|--|
|     | Product definition:  | Mixture   |  |  |  |  |
|     | Classification of the mixture:   | Reproductive to   | xicity (Category 1B), H360   |  |  |  |
| 2.2 | 2 Label Elements:  |   |  |  |  |  |
|     | Signal Word:   | Danger  |  |  |  |  |
|     | Hazard statement:  | H360: May damage fertility or the unborn child                          |  |  |  |  |
|     | Adverse Human Health Effects and Symptoms:   | Presumed human reproductive toxicant – largely based on animal evidence |  |  |  |  |
|     | Pictograms:  |   |  |  |  |  |
|     | Precautionary Statements:  |   |  |  |  |  |
|     |  | P201  | Obtain special instructions before use                                       |  |  |  |
|     | Precautionary Statement Prevention:  | P202  | Do not handle until all safety precautions have been read and understood.    |  |  |  |
|     |  | P280  | Wear protective gloves/ protective clothing/ eye protection/ face protection |  |  |  |
|     | Precautionary Statement Response:  | P308 + P313   | If exposed or concerned get medical advice/attention.                        |  |  |  |
|     | Precautionary Statement Storage:   | P405  | Store in location with controlled access                                     |  |  |  |
|     | Precautionary Statement Disposal:  | P501  | Dispose of contents/container to a licensed disposal company                 |  |  |  |

#### 2.3 Other Hazards not Otherwise Classified:

This product contains human plasma. Source material used in these products was found to be negative when tested in accordance with current FDA required tests for communicable disease. However, no known test methods can offer complete assurance that products derived from human blood will not transmit infectious agents. Accordingly, any human blood-based component should be handled and discarded as recommended for any potentially infectious human specimen.



Revision date: April 27, 2020

#### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

3.1. Substance/Mixtures: Mixture

| Component Name | EC-No     | CAS-No   | Concentration  | Classification   |
|----------------|-----------|----------|--|--|
| Imidazole      | 206-019-2 | 288-32-4 | 0.1 <c<1%< td=""><td>Acute toxicity, Oral (Category 4), H302 Skin corrosion (Category 1B), H314 Serious eye damage (Category 1), H318 Reproductive toxicity (Category 1B), H360</td></c<1%<> | Acute toxicity, Oral (Category 4), H302 Skin corrosion (Category 1B), H314 Serious eye damage (Category 1), H318 Reproductive toxicity (Category 1B), H360 |

For the full text of the H-Statements mentioned in this Section, see Section 16.

#### **SECTION 4. FIRST AID MEASURES**

#### 4.1 Description of First Aid Measures

If inhaled, move person to fresh air. Get medical attention if adverse Inhalation:

symptoms appear

Remove contaminated clothes and shoes. Wash affected area immediately Skin Contact:

with soap or mild detergent and plenty of water. Get medical attention if

symptoms occur

Rinse immediately with plenty of water. Keep eyelid open with fingers while Eye Contact:

rinsing. Check for and remove any contact lenses. Get medical attention if

irritation occurs

Rinse mouth with plenty of water provided person is conscious. Do not Ingestion:

induce vomiting. Get medical attention if symptoms occur

### 4.2 Most Important Symptoms and Effects, Acute and Delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11.

#### 4.3 Immediate Medical Attention and Special Treatment

Note to physician: In case of exposure, the symptoms might be delayed. The exposed person

may need to be kept under medical surveillance for 48 hours

No action shall be taken involving any personal risk or without suitable training



Doc. ID: SDS-002 EN Revision: 01

Revision date: April 27, 2020

#### **SECTION 5. FIRE-FIGHTING MEASURES**

#### 5.1 Extinguishing Media

Suitable Extinguishing Media: Product is non-flammable, low risk of fire by the inflammability

> characteristics of the product in normal conditions of storage, manipulation and use. In the case of the existence of sustained combustion as a result of improper manipulation, storage or use any type of extinguishing agent

can be used

Unsuitable Extinguishing Media: Not applicable

#### 5.2 Specific Hazards Arising from the substance or mixture

Specific hazards arising from the chemical/substance or mixture:

Due to its non-flammable nature, the product does not present a fire risk

under normal conditions of storage, manipulation and use

Hazardous thermal decomposition products:

Thermal decomposition may generate toxic and hazardous fumes of

carbon oxides, nitrogen oxides, hydrogen cyanide

#### 5.3 Special Protective Equipment and Precautions/Advice for Fire-Fighters

Protective actions: Isolate the scene by removing all persons from the vicinity of the incident if

there is fire. No action shall be taken involving any personal risk or without

suitable training

Equipment for self-protection: Depending on the magnitude of the fire it may be necessary to use full

protective clothing and individual respiratory equipment. Minimum

emergency facilities and equipment should be available.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

#### 6.1 Personal Precautions, Protective Equipment, and Emergency Procedures

For non-emergency personnel: Isolate leaks provided that there is no additional risk for the people

performing this task. Do not walk through spilled material. Put on

appropriate personal protective equipment

Wear appropriate protective equipment (see Section 8). See also the For emergency responders:

information in "For non-emergency personnel"

#### 6.2 Environmental Precautions

Keep product away from drains, surface and underground water

#### 6.3 Methods for Containment and Cleaning Up

Pre-treat the spill with a disinfectant with full biocidal activity. Soak up with inert absorbent material, and clean with plenty of water. Collect spilled material in appropriate waste disposal container. Dispose of via a licenced waste disposal contractor

#### 6.4 Reference to Other Sections

See Section 1 for emergency contact information

See Section 8 for information on appropriate personal protective equipment

See Section 13 for additional waste treatment information

#### **SECTION 7. HANDLING AND STORAGE**



Revision date: April 27, 2020

#### 7.1 Precautions for Safe Handling

All blood products should be treated as potentially infectious. Human blood-based products should be handled and discarded as recommended for any potentially infectious human specimen

Protective measures: Put on appropriate personal protective equipment (see Section 8)

Advice on general occupational hygiene: Do not eat, drink or smoke in areas where this mixture is handled, stored

> and processed. Wash hands with soap and water after handling the mixture and before eating, drinking or smoking. Remove contaminated clothing and protective equipment before entering eating areas. See Section 8 for additional information on hygiene measures

#### 7.2 Conditions for Safe Storage, Including Any Incompatibilities

Store at temperature indicated on the product label. Keep container tightly closed and sealed until ready for use. Avoid environmental release. Keep away from food and drinks. Store in accordance with local regulations

#### 7.3 Specific End Uses

The product is for use with the other components of CRYOcheck Factor VIII Inhibitor Kit. CRYOcheck Factor VIII Inhibitor Kit is intended for in vitro diagnostic use. Use the product in accordance with Good Laboratory Practice

#### **SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

8.1 Control Parameters: None

8.2 Exposure Controls: No exposure limit value known.

#### 8.2.1 Appropriate Engineering Controls

Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

#### 8.2.2 Individual Protection Measures

Eye/Face Protection:

Skin Protection:

Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following

protection should be worn, unless the assessment indicates a higher

degree of protection: safety glasses with side-shields

Handle with chemical-resistant, impervious gloves complying with an approved standard. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash

and dry hands

Respiratory Protection: Respiratory protection is not required

Personal protective equipment (PPE) should be selected based on the **Body Protection:** 

task being performed and the risks involved



Doc. ID: SDS-002 EN Revision: 01

Revision date: April 27, 2020

Other skin protection:

Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved

**8.2.3 Environmental Exposure Controls** Avoid any release into the environment

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

#### 9.1 Information on Basic Physical and Chemical Properties

Physical state: Liquid

Odor: Odorless

Odor Threshold: Not applicable

Color: Yellowish

pH: pH 7.3-7.5

Melting point/freezing point: Not available

Initial boiling point and boiling range: Not available

Flash point: Product does not sustain combustion

Evaporation rate: Not available Flammability: Not applicable

Upper/lower flammability or explosive

limits:

Not applicable

Vapor Pressure: Not available

Vapor density: Not applicable
Relative Density: Not applicable

Solubility: Not applicable

Partition coefficient: n-octanol/water: Not applicable

Auto-ignition temperature: Not applicable

Decomposition temperature: Not applicable

Viscosity: Not applicable

Explosive properties: Not applicable

Oxidizing properties: Not applicable

**9.2 Other Information:** Not applicable



Revision date: April 27, 2020

#### **SECTION 10. STABILITY AND REACTIVITY**

#### 10.1 Reactivity

No specific test data related to reactivity available for this product or its ingredients.

#### 10.2 Chemical Stability

Chemically stable under recommended conditions of storage, handling and use.

#### 10.3 Possibility of Hazardous Reactions

Under the normal conditions of storage and use, hazardous reactions will not occur.

#### 10.4 Conditions to Avoid, Including Static Discharge, Shock or Vibration

Not applicable

#### 10.5 Incompatible Materials

Avoid strong acids, avoid alkalis or strong bases

#### 10.6 Hazardous Decomposition Products

Under normal conditions of storage and use, hazardous decomposition products should not be produced

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

#### 11.1 Information on Toxicological Effects

be a potential carcinogen by OSHA:

| Acute toxicity:  | Not available    |
|--|------------------|
| Skin corrosion/irritation:   | Not available    |
| Serious eye damage/irritation:   | Not available    |
| Respiratory or skin sensitization:   | Not available    |
| Germ cell mutagenicity:  | Not available    |
| Carcinogenicity:   | Not available    |
| Reproductive toxicity:   | Not available    |
| Summary of evaluation of the CMR properties:   | Not available    |
| STOT-single exposure:  | Not available    |
| STOT-repeated exposure:  | Not available    |
| Aspiration hazard:   | Not available    |
| Symptoms related to the physical, chemical and toxicological characteristics:  | No specific data |
| Delayed and immediate effects, and chronic effects from short-term and long-term exposure:   | Not available    |
| Numerical measures of toxicity, including Acute Toxicity Estimates (ATEs):   | Not available    |
| Indication of whether the chemical is listed in the National Toxicology Program (NTP) Report on Carcinogens (latest edition) or has been found to be a potential carcinogen in the International Agency for Research on Cancer (IARC) Monographs (latest editions) or found to | Not found        |



Revision date: April 27, 2020

#### **SECTION 12. ECOLOGICAL INFORMATION**

12.1 Toxicity: Not available

12.2 Persistence and Degradability: Not available

12.3 Bioaccumulative Potential: Not available

12.4 Mobility in Soil: Not available

12.5 Results of PBT and vPvB Assessment: Not applicable

12.6 Other Adverse Effects: No known significant effects or critical hazards.

#### **SECTION 13. DISPOSAL CONSIDERATIONS**

#### 13.1 Disposal Methods and Special Precautions for Product Disposal

The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licenced waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction

#### **Special Precautions**

The product is a human blood-based product and should be handled and discarded as recommended for any potentially infectious human specimen

#### 13.2 Disposal Methods for Packaging

The generation of waste should be avoided or minimized wherever possible. Incineration or landfill should only be considered when recycling is not feasible

#### **Special Precautions**

This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers

#### **SECTION 14. TRANSPORT INFORMATION**

(ADR/RID, ADN, IMDG and ICAO, TDG&DOT Classification, IATA)

14.1 UN Number: Not regulated

14.2 UN Proper Shipping Name: Not applicable

14.3 Transport Hazard Class: Not applicable

14.4 Packing Group: Not applicable

14.5 Environmental Hazards: Not applicable

14.6 Additional Information: Not applicable

#### 14.7 Special Precautions for User



Doc. ID: SDS-002 EN Revision: 01

Revision date: April 27, 2020

Transport within user premises: Always transport in closed containers that are upright and secure. Ensure

that persons transporting the product know what to do in the event of an

accident or spillage

14.8 Transport in Bulk According to Annex

II of MARPOL and the IBC Code:

Not applicable

#### **SECTION 15. REGULATORY INFORMATION**

### 15.1 Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada Regulations and Lists:

NPRI: No components listed

CEPA Toxic substances: No components listed

DSL/NDSL: All components are listed or exempt

US Regulations and Lists:

TSCA: All components are listed or exempt

SARA 302/304 and Not applicable

SARA 311/312 Imidazole: Acute Health Hazard, Chronic Health Hazard

Massachusetts No components listed

**New Jersey** Imidazole, CAS# 288-32-4 Pennsylvania Imidazole, CAS# 288-32-4

California Prop. 65 No components listed

EU Regulations and Lists:

EU Regulation (EC) No.1907/2006 (REACH):

Annex XIV List of substances subject to

authorisation

No components listed

Annex XVII Restrictions on the manufacture, placing on the market and use of certain dangerous substances,

mixture and articles

Not applicable

C&L Inventory, REACH # 01-2119485825-24-XXXX

#### 15.2 Chemical Safety Assessment

No Chemical Safety Assessment has been carried out for this substance/mixture by the supplier

#### **SECTION 16. OTHER INFORMATION**

Full text of H-Statements Referred to Under Section 2



Doc. ID: SDS-002 EN Revision: 01

Revision date: April 27, 2020

H302: Harmful if swallowed

H314: Causes severe skin burns and eye damage

H318: Causes serious eye damage

H360: May damage fertility or the unborn child

Repr: Reproductive toxicity

#### **Key literature References and Sources for Data**

This SDS was prepared on the basis of sheets of individual components and online databases (e.g. ECHA, RTECS) as well as our knowledge and experience, taking into account current legislation

#### **Procedure Used to Derive the Classification for Mixtures**

(EU) Classification for mixtures according to Regulation (EC) 1272/2008 [CLP] Hazard Communication Standard, 29 CFR 1910.1200 (HCS) Hazardous Product Regulation HPR (WHMIS 2015)

#### **Training Advice**

Provide workers with adequate training to assure that the product is handled safely in accordance with national and community legislation

#### **Abbreviations and Acronyms:**

WHMIS=Workplace Hazardous Materials Information System

GHS=Globally Harmonized System of Classification and Labelling of Chemicals

OSHA=Occupational Safety and Health Administration

CLP= Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]

FDA=Food and Drug Administration

STOT=Specific Target Organ Toxicity

PBT=Persistent, Bioaccumulative and Toxic

vPvB= Very Persistent and very Bioaccumulative

ADR=European Agreement concerning the International Carriage of Dangerous Goods by Road

RID=European Agreement Concerning the International Carriage of Dangerous Goods by Rail

ADN=International Carriage of Dangerous Goods by Inland Waterways

IMDG=International Maritime Dangerous Goods

ICAO= International Civil Aviation Organization

TDG=Transportation of Dangerous Goods Act

**DOT=Department of Transportation** 

UN=United Nations

IATA=International Air Transport Association

NPRI=National Pollutant Release Inventory

CEPA=Canadian Environmental Protection Act

DSL=Canada Domestic Substances List

NDSL= Canada Non-Domestic Substances List

TSCA=Toxic Substances Control Act

SARA=Superfund Amendments and Reauthorization Act

DEA Lists=United States Drug Enforcement Administration Lists

EPA=United States Environmental Protection Agency

REACH=Registration, Evaluation, Authorisation and Restriction of Chemicals

ECHA=European Chemical Agency

RTECS=Registry of Toxic Effects of Chemical Substances

#### Notice to Reader:

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.



Doc. ID: SDS-002 EN

Revision: 01

Revision date: April 27, 2020

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist

#### **Preparation Information**

Precision Biologic Inc.

### **Revision History**

Revision: 00 Revision Date: April 9, 2019 Changes: Not applicable

Revision: 01 Revision Date: April 27, 2020 Changes: Updates for clarity, including updates to

Section 2.3